KEDI Global Longevity Bio Index

FDA decision (PDUFA date) for brepocitinib in dermatomyositis (DM) on 2026-09-30 expected

Quarterly dividend of $0.47 per share, with an ex-dividend date of September 15, 2026, scheduled.

First quarter 2027 earnings release on 2026-08-10 scheduled

Q2 2026 earnings release and conference call scheduled.

Viatris is scheduled to report its second-quarter 2026 financial results on August 6, 2026, scheduled.

High importance is estimated due to the potential for significant market volatility following the report; Q2 2026 earnings release is scheduled.

FDA PDUFA target action date for seasonal flu vaccine candidate mRNA-1010. A decision on approval is expected. High importance estimated due to potential for >=10% price impact.

Q2 2026 earnings and financial results for the first half of 2026 are scheduled to be announced on August 5, 2026; this scheduled event is estimated to have a low price impact (1-5%) scheduled.

Pfizer is scheduled to release its Q2 2026 earnings report before the market opens on August 4, 2026. Analysts forecast EPS of $0.68 and revenue of $14.45 billion, forecasted. High importance is estimated due to typical high volatility during earnings releases, scheduled.

Amgen is scheduled to report its Q2 2026 financial results after the market closes on August 4, 2026; analysts forecast an EPS of approximately $5.57-$5.60. This event is assigned Medium importance as earnings reports typically cause price shifts of 5% or more scheduled.

Merck to release its second-quarter 2026 financial results on August 4, 2026, before the market opens; low impact expected.

AbbVie announced on June 26, 2026, that it will report its second-quarter 2026 financial results on July 31, 2026, before the market opens, scheduled. High importance is estimated due to the potential for significant market volatility following the earnings report.

Q2 2026 earnings release scheduled. High importance estimated due to potential for >=10% price impact.

Alnylam is scheduled to report its second quarter 2026 financial results on July 30, 2026, before market open; high importance is assigned due to the potential for price impact exceeding 10% scheduled

Illumina to announce Second Quarter 2026 financial results after market close on July 30, 2026; high importance estimated due to potential for over 10% price impact based on historical volatility, scheduled.

Bristol Myers Squibb is scheduled to announce its financial results for the second quarter of 2026 on July 30, 2026, before the market opens, followed by a conference call with executives. This is a recurring event with the potential for moderate stock price volatility based on results and guidance. This event is scheduled.

Regeneron is scheduled to report its second quarter 2026 financial and operating results before the U.S. financial markets open, as announced on June 25, 2026. Importance is estimated as Medium because quarterly earnings reports for large-cap biotech companies often result in price movements exceeding 5%. This is scheduled

Q2 2026 earnings release scheduled. Medium importance as a standard quarterly financial update to assess fiscal health.

Quarterly results typically drive price volatility of ≥5%; therefore, the first quarter fiscal year 2026 earnings release is scheduled.

Teva is scheduled to release its second quarter 2026 financial results on 2026-07-29 scheduled. High importance is estimated due to the historical volatility associated with quarterly earnings reports.

Biogen is scheduled to report its Q2 2026 financial results on July 29, 2026, before the market opens, followed by a conference call; a medium impact is estimated based on historical earnings volatility, expected.

Ionis will host a webcast to discuss its second quarter 2026 financial results on July 29, 2026, scheduled.

GSK is scheduled to announce its second quarter 2026 financial results, expected.

IQVIA Holdings is scheduled to announce its second-quarter 2026 financial results on July 28, 2026. High importance is estimated due to the significant market impact typical of earnings releases, scheduled.

AstraZeneca is scheduled to announce its H1 and Q2 2026 financial results on July 27, 2026. High importance is estimated due to the potential for a price impact of 10% or more from the semi-annual results, scheduled.

Ex-dividend date for the Q3 2026 dividend of $0.43 per share on July 24, 2026. Low importance is estimated as dividend events are routine and typically result in price adjustments equal to the dividend amount, scheduled.

RELX is scheduled to release its H1 2026 earnings results on July 23, 2026, scheduled. High importance estimated due to the significant historical impact of H1 results on annual guidance.

Q2 2026 earnings results are scheduled to be released before the market opens on July 23, 2026. Analysts forecast EPS of approximately $5.71 on revenue of $11.70 billion, forecasted.

Q2 2026 earnings release. High importance is estimated given the significant market volatility following the previous quarter's results, scheduled

Novartis Q2 2026 financial results are scheduled to be released before the market opens on July 21, 2026, with analysts forecasting an EPS of around $2.15-$2.17. Earnings releases typically result in a price impact of approximately 5%. scheduled

GSK announced that the European Medicines Agency (EMA) accepted its submission to update the label for its Bexsero (meningitis B) vaccine to include a single-dose booster for individuals aged 10 years and older.

GSK announced it will discontinue the development of camlipixant for refractory chronic cough (RCC) after mixed results from its CALM-1 and CALM-2 Phase III trials. One study met its primary endpoint while the other failed, leading the company to conclude the drug was unlikely to transform patient care. The drug was the lead asset from the $2 billion acquisition of Bellus Health in 2023.

The US Food and Drug Administration (FDA) granted traditional (full) approval for Fabhalta (iptacopan) on July 17, 2026, to slow kidney function decline in adults with primary IgA nephropathy (IgAN). This converts the accelerated approval granted in 2024.

Reported Q2 2026 earnings with adjusted EPS of $1.31, beating estimates of ~$1.28. Revenue was ~$12.5 billion, slightly missing estimates. The company raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60. The stock rose over 11% in pre-market trading.

The U.S. FDA approved Lipfendra (enlicitide) on July 16, 2026, as the first once-daily oral PCSK9 inhibitor; high impact expected due to first-in-class status.

Announced positive secondary endpoint data from Phase 3 trials for zasocitinib in psoriasis; a ≥5% price impact is estimated.

Announced the first U.S. participant was dosed in the Phase 1 study of mRNA-4200, an investigational tumor-targeted cancer antigen therapy for solid tumors.

The European Commission granted marketing authorisation for the Wegovy pill (oral semaglutide 25 mg) for weight management on July 15, 2026; this first-in-class approval is estimated to have a high price impact (>10%).

Johnson & Johnson reported Q2 2026 earnings on 2026-07-15, with revenue of $25.3 billion and adjusted EPS of $2.90, beating analyst expectations and raising full-year guidance.

On July 15, 2026, Alnylam presented progress on its neuroscience programs at the Alzheimer's Association International Conference (AAIC) 2026, including updates on studies for Alzheimer's disease and related disorders.

Biogen announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026.

AstraZeneca announced on July 14, 2026, that it entered into an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy, an oral lung cancer drug.

Biogen presented detailed Phase 2 data for its Alzheimer's drug diranersen, which missed its primary endpoint but showed a 26% slowing of cognitive decline at its lowest dose. The stock fell over 8% following the news.

Merck's partner Kelun-Biotech announced on July 14, 2026, that a Phase 3 trial of sac-TMT with KEYTRUDA met its primary endpoint; medium impact expected as it strengthens the oncology pipeline.

On July 14, 2026, a Munich court ruled Illumina infringed on a DNA sequencing patent held by Element Biosciences, ordering a recall of MiSeq systems in Germany, resulting in a 3% stock decline.